Literature DB >> 7923622

Neutral endopeptidase in the heart. Neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation.

G Piedimonte1, J A Nadel, C S Long, J I Hoffman.   

Abstract

Peptide mediators may play a role in the control of myocardial perfusion. We found immunohistochemical evidence of the peptide-degrading enzyme neutral endopeptidase (NEP) in cultured rat myocytes. Therefore, we examined the effect of an NEP inhibitor, phosphoramidon, on myocardial perfusion in rats after (1) stimulating sensory nerves with capsaicin and (2) inducing myocardial hypoperfusion with isoproterenol, with or without pretreatment with selective antagonists of the substance P (NK1) and bradykinin (B2) receptors. Three to five sequential determinations of myocardial blood flow were made in anesthetized rats by injecting 100,000 radionuclide-labeled microspheres suspended in 70% dextrose into the left ventricle. Phosphoramidon doubled coronary blood flow in response to a dose of capsaicin that was ineffective in the absence of the inhibitor. Isoproterenol (50 mg/kg IP) caused an immediate fall in blood pressure and coronary blood flow; after 20 minutes, flow had returned to normal but pressure was still subnormal. Administration of phosphoramidon reduced the recovery of blood pressure but greatly increased coronary blood flow. These changes were not altered by a substance P NK1 receptor blocker but were completely abolished by a selective bradykinin B2 receptor blocker. Our data indicate that (1) NEP is present in the rat myocardium, (2) sensory nerve-induced coronary vasodilation is markedly potentiated by NEP inhibition, (3) isoproterenol-induced myocardial hypoperfusion is prevented by NEP inhibition, and (4) this effect of NEP inhibition is due to reduced degradation of bradykinin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923622     DOI: 10.1161/01.res.75.4.770

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  11 in total

Review 1.  Role of bradykinin in preconditioning and protection of the ischaemic myocardium.

Authors:  G F Baxter; Z Ebrahim
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

Review 2.  Salvage of jeopardized myocardium by ischemic preconditioning: is the quest over?

Authors:  R Strasser; P Htun; W Schaper
Journal:  Mol Cell Biochem       Date:  1996 Jul-Aug       Impact factor: 3.396

3.  The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin.

Authors:  M A Rastegar; F Marchini; G Morazzoni; A Vegh; J G Papp; J R Parratt
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

Review 4.  Long-term neprilysin inhibition - implications for ARNIs.

Authors:  Duncan J Campbell
Journal:  Nat Rev Cardiol       Date:  2016-12-15       Impact factor: 32.419

5.  Intracardiac expression of neutral endopeptidase.

Authors:  V Raizada; W Luo; B J Skipper; P G McGuire
Journal:  Mol Cell Biochem       Date:  2002-03       Impact factor: 3.396

6.  Effect of endopeptidase-24.11 inhibitors and C-ANP receptor ligand on responses evoked in arterioles of rat cremaster muscle by atrial natriuretic peptide.

Authors:  J Peyroux; F Beslot; N Claperon; M C Fournie-Zaluski; B P Roques
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

7.  Effect on prolonged inhibition of neutral endopeptidase on cardiac hypertrophy in rats with myocardial infarction.

Authors:  C Marie; C Mossiat; C Gros; T Monteil; J Bralet
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

8.  Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure.

Authors:  Toshiyuki Maki; Yoshihisa Nasa; Kouichi Tanonaka; Masaya Takahashi; Satoshi Takeo
Journal:  Mol Cell Biochem       Date:  2003-12       Impact factor: 3.396

Review 9.  Neprilysin Inhibitors and Bradykinin.

Authors:  Duncan J Campbell
Journal:  Front Med (Lausanne)       Date:  2018-09-19

Review 10.  The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.

Authors:  Massimo Volpe; Marino Carnovali; Vittoria Mastromarino
Journal:  Clin Sci (Lond)       Date:  2016-01       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.